Status: Recruiting
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
This phase II trial tests how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.
Participants needed: 40
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Emory UniversityUpdated: Sep 25, 2025Locations: 5
Eligibility criteria
Patients with resected pathologic stage IIB, IIC and III dMMR colon cancer (Amer... [+20]
Neoadjuvant treatment for dMMR colon cancer [+11]